1.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

2.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

3.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

4.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

5.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

6.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

7.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

8.

Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study

1.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

2.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

3.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

4.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

5.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

6.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

7.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

1.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

2.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

3.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

4.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

5.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

6.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

7.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

1.

Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge. ; Insulin detemir in the predictive study: result...

2.

Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge. ; Insulin detemir in the predictive study: result...

3.

Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge. ; Insulin detemir in the predictive study: result...

4.

Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge. ; Insulin detemir in the predictive study: result...

1.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

2.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

3.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

4.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

5.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

6.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

7.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

1.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

2.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

3.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

4.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

5.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

6.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

7.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

1.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

2.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

3.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

4.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

5.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

6.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

7.

Effets du glimepiride (Amarylle) chez le patient diabétique de type 2: Résultats de l'étude belge RECORD en médecine générale. ; Effects of glimepiride (Amarylle) in type 2 diabeti...

1.

De l'utilité d'une consultation conjointe de gynécologie- endocrinologie pédiatrique : étude rétrospective des motifs de consultation et approche pratique ; The usefulness of combi...

2.

De l'utilité d'une consultation conjointe de gynécologie- endocrinologie pédiatrique : étude rétrospective des motifs de consultation et approche pratique ; The usefulness of combi...

1.

Les nouvelles recommandations Europeennes pour le traitement des dyslipidemies en prevention cardiovasculaire. ; New European guidelines for the management of dyslipidaemia in card...

2.

Les nouvelles recommandations Europeennes pour le traitement des dyslipidemies en prevention cardiovasculaire. ; New European guidelines for the management of dyslipidaemia in card...

1.

The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients.

2.

The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients.